Research protocol · PRO-2026-001

Symptoms beyond diagnostic boundaries: scoping, observation vocabulary, and safety protocol

A concern does not become research until its practical boundaries are stated. We need to decide which patients can be studied together, which must remain separate, when missed disease should be reconsidered, and what can be observed without imposing excessive burden. This protocol is the first working design for that task.

What this record asks

A public v0.1 protocol that first separates terms and patient strata, combines red-flag reassessment with low-burden longitudinal observation, and constructs comparable phenomenon units across classical sources, cases, and contemporary research.

What it aims to change

Formalises a dual track that preserves diagnostic openness and therapeutic research without turning “unexplained” into a psychogenic conclusion.

Previous and next records

Where this idea came from and where it leads

  1. OP-2026-001How can symptoms beyond diagnostic boundaries be observed and studied safely?

    The problem motivates a protocol for researchable strata, vocabulary, and safety rules.

  2. CON-2026-001Conjecture of added clinical value from temporal, contextual, symptom-network phenotypes

    Future observational studies are designed to test the phenotype’s incremental value.

  3. LCB-2026-001Candidate dual-track care and minimum longitudinal observation set

    Translates dual-track principles into low-burden observation candidates, not treatment advice.

Show verification requirements and current limitations

What still needs to be established

  • Terminology review by clinicians, methodologists, and people with lived experience
  • Link condition-specific red flags to established guidance and specialist pathways
  • Approve ethics, consent, privacy, and analysis plans before human data collection

What this record does not yet establish

  • This founding protocol is public but remains v0.1 before external review; it is not a patient-screening instrument or clinical guideline.